RYTHM (NASDAQ:RYM – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.
Earnings & Valuation
This table compares RYTHM and ARS Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RYTHM | $17.28 million | 2.41 | -$33.26 million | ($10.53) | -1.81 |
| ARS Pharmaceuticals | $84.28 million | 4.73 | -$171.30 million | ($2.18) | -1.84 |
Profitability
This table compares RYTHM and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | -6.20% | -12.57% | -2.60% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Institutional & Insider Ownership
6.0% of RYTHM shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
RYTHM has a beta of 9.46, meaning that its stock price is 846% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for RYTHM and ARS Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 524.22%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than RYTHM.
Summary
ARS Pharmaceuticals beats RYTHM on 8 of the 14 factors compared between the two stocks.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.
